drugset / Trial / NCT04479579

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

NCT04479579

Phase 4 Completed 53 enrolled McMaster University
NaSingle-groupOpen-labelPrevention

Summary

This is a prospective, twin-center, cohort study in patients discharged from the hospital after major abdominal or pelvic cancer surgery for cancer. This study is designed to evaluate the adherence to extended deep vein thrombosis prophylaxis (DVT) with the direct oral anticoagulant apixaban on the background of historical data from the investigator's center on low-molecular-weight heparin (LMWH) substandard adherence in the same setting.

Timeline

Start
2021-02-22
Primary completion
2021-10-31
Completion
2021-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral